Arena Stumbles On EMA Concerns Over Belviq Ahead Of Launch

By Brian L. Wilson We’ve seen no shortage of recent volatility in shares of Arena Pharmaceuticals (ARNA), which moved down over 9.7% just yesterday (Wednesday) based on commentary ...

Biogen’s Longer-Lasting MS Drug Meets Goals in Late Trial

By Meg Tirrell Biogen Idec Inc. (BIIB)’s longer-lasting injectable multiple sclerosis drug, peginterferon beta-1a, helped reduce the risk of relapse by 36 percent when given every ...

Alnylam: Rally On No News Leaves Room For Downside

By Apsara Biotechnology Research Since we wrote our first article on Alnylam (ALNY), the stock has risen 30%, making what was previously merely an overvalued stock now reach nosebleed ...

Amgen 4Q profit drops 16 pct. on higher spending

Drugmaker Amgen’s 4Q profit tumbles 16 pct, as higher spending offsets increased product sales By Linda a. Johnson Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop ...

US Investigates Novartis Over Alcon Sales To Iran

By Ed Silverman As if Novartis did not have enough troubles, the US Attorney in Texas is investigating the sale of Alcon eye healthcare products to various countries that are subject ...

Gilead Petitions FDA Over Its Stribild AIDS Med

By Ed Silverman In a challenge to FDA decisionmaking that will be closely watched by the pharmaceutical industry, Gilead Sciences has asked the agency to grant five years of exclusivity ...

FDA approves new use for Roche’s Avastin in colon cancer treatment

(Reuters) – The U.S. Food and Drug Administration on Wednesday approved the use of Roche’s Avastin for patients whose colorectal cancer has worsened despite previous treatment ...

Merck CEO says jury out on raising good cholesterol

By Ben Hirschler DAVOS, Switzerland (Reuters) – The jury is still out on the benefits of increasing “good” HDL cholesterol, but the strategy remains worth pursuing, ...

Watson buys Uteron of Belgium in $305 million deal

By KEVIN GROGAN Watson Pharmaceuticals has expanded its women’s health franchise with the acquisition of Belgium’s Uteron Pharma. The US generics major is paying $150 million ...

Cellceutix Reports In Vivo Tumor Shrinkage in Renal Cancer

By Cellceutix BEVERLY, MA– Cellceutix Corporation ( OTCBB : CTIX ) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule ...

FDA slaps Class I tag on Bausch + Lomb’s eye surgery recall

By Damian Garde Bausch + Lomb is recalling cannulas shipped with its eye surgery devices over risks that they might leak or break during procedures, and the FDA has affixed its ...

AngioDynamics spends $15M on microwave ablation tech

By Damian Garde AngioDynamics ($ANGO) is spending $15 million to acquire minimally invasive microwave ablation technology from Microsulis Medical. The company already had distribution ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS